Pressure BioSciences Inc (OTCMKTS:PBIO) has received a purchase order from a new customer for its proprietary BaroShear K45 Ultra Shear Technology platform for processing CBD oil.
In a statement Thursday, the Massachusetts-based company said Can B Corp (OTCMKTS:CANBD) issued the purchased order for its UST system that processes CBD oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water.
Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the absorption efficiency of today's macro or microemulsions of CBD oil.
CBD is extracted from the hemp plant in oil, and as with any oil-based product, it is difficult for the water-based biology of human bodies to access and absorb CBD molecules from relatively large hemp oil droplets, Pressure Biosciences said.
These poor and variable absorption levels of CBD result in low and variable bioavailability of the CBD molecules available in the body for the treatment of targeted conditions. Low or widely varying levels of CBD absorption and bioavailability may significantly impact the effective delivery of the potential benefits of many CBD products on the market today.
"It is apparent to us that PBI's breakthrough UST platform is emerging as a pivotal market-changing technology enabling a new generation of CBD and other cannabinoid products to more effectively meet supplier objectives and consumer demands,” said Marco Alfonsi, CEO of Can B.
“Offering effective water solubility of cannabinoids, PBI's UST-based BaroShear K45 system is expected to produce high CBD absorption rates and bioavailability from ingestion or topical application of cannabinoid products."
Alfonsi said the BaroShear K45 system is expected to be delivered in the fourth quarter of 2020.
“We are excited to be one of only a handful of companies worldwide that will be among the first to have the ability to process cannabinoid products with this revolutionary nanoemulsification system. We believe the UST-based BaroShear K45 will allow us to reach levels of absorption and bioavailability in our products that far exceed that of other manufacturers on the market today."
Pressure BioSciences CEO Richard Schumacher commented: "Importantly, the optimized effectiveness for the consumer also translates into allowing top-shelf manufacturers like Can B Corp to achieve targeted product effects from much lower levels of cannabinoids in their marketed products. This should offer them a dramatic new cost efficiency, for both ingested or topically applied products. We also believe that Can B Corp's routine use of our BaroShear K45 system will allow them to increase even more the current high-quality level of their products."
UST platform potential
Pressure BioSciences Chairman Jeffrey Peterson framed a larger perspective on the potential of the company’s UST platform.
"When I first discovered PBI's unique high-pressure technologies being applied to extremely challenging life sciences problems many years ago, my chemical engineering education at MIT suddenly stood at attention," he said.
“The insights of thermodynamics illuminated a wide range of valuable application possibilities extending far beyond PBI's initial and successful breakthroughs as a ‘gentle giant’ in sample preparation required by thousands of scientists prior to analytical testing. A decade later, our innovation of Ultra Shear Technology is allowing valuable materials that exist as oils (and thus do not naturally mix with water) to finally be prepared in effectively water-soluble preparations that can be easily absorbed by the water-based biology of our bodies, without requiring heavy use of undesirable chemical additives."
Peterson added: "In addition to playing a significant role in the projected $89 billion (by 2024) cannabinoids market, we expect our patented UST technology platform to transform a vast range of applications that extend across many multi-billion-dollar markets, from dairy and other foods/beverages, to pharmaceuticals, nutraceuticals, and industrial applications.”
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham